Upstream Bio, Inc. Cash Flow Conversion Efficiency
Upstream Bio, Inc. cash flow conversion efficiency. Based on the latest financial reports, Upstream Bio, Inc. (UPB) has a cash flow conversion efficiency ratio of -0.131x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-35.62 Million) by net assets ($270.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Upstream Bio, Inc. (2022–2025)
Cash flow conversion efficiency of Upstream Bio, Inc. from 2022 to 2025. This chart illustrates how Upstream Bio, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Upstream Bio, Inc. for real-time trading data and today's change.
Upstream Bio, Inc. Cash Flow Conversion Ratio Explained
Upstream Bio, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Upstream Bio, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Upstream Bio, Inc. ranked by their cash flow conversion efficiency. Also see UPB market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AG Mortgage Investment Trust Inc
NYSE:MITT
|
0.037x |
|
Soosan Industries Co. Ltd.
KO:126720
|
0.015x |
|
MSP Steel & Power Limited
NSE:MSPL
|
0.098x |
|
Solarius Capital Acquisition Corp.
NASDAQ:SOCA
|
0.000x |
|
Ceragon Networks Ltd
NASDAQ:CRNT
|
0.029x |
|
SR Accord
TA:SRAC
|
-0.090x |
|
The Reject Shop Ltd
AU:TRS
|
0.447x |
|
Sinphar Pharmaceutical Co Ltd
TW:1734
|
0.031x |
Annual Cash Flow Conversion Efficiency for Upstream Bio, Inc. (2022–2025)
The table below shows the annual cash flow conversion efficiency of Upstream Bio, Inc. from 2022 to 2025. Review UPB financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $339.77 Million | $-133.28 Million | -0.392x | -211.46% |
| 2024-12-31 | $469.85 Million | $-59.17 Million | -0.126x | -140.89% |
| 2023-12-31 | $-123.13 Million | $-37.93 Million | 0.308x | +71.91% |
| 2022-12-31 | $-106.16 Million | $-19.02 Million | 0.179x | -- |
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.… Read more